Apricus Biosciences (NASDAQ:APRI)

CAPS Rating: 2 out of 5

A pharmaceutical and medical technology company, which conducts research and development both domestically and abroad on proprietary pharmaceutical products.

Recs

1
Player Avatar spikenail (< 20) Submitted: 6/13/2007 12:21:43 PM : Outperform Start Price: $31.20 APRI Score: -140.70

Biotech....pharma tech.....these are the companis that are making all the money in the pharma sector.

Member Avatar beji1921 (< 20) Submitted: 4/29/2010 8:53:34 PM
Recs: 0

FDA allow this company to bypass Phase II trial. I beleive this company has some good news sitting in the pipeline. They are making medicine for liver cancer and liver metastasis. I believe this is a Nuke in biotech sector

Featured Broker Partners


Advertisement